News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
488,659 Results
Type
Article (8613)
Company Profile (140)
Press Release (479905)
Multimedia
Podcasts (10)
Webinars (6)
Section
Business (167844)
Career Advice (313)
Deals (25877)
Drug Delivery (14)
Drug Development (53415)
Employer Resources (16)
FDA (9855)
Job Trends (8626)
News (239942)
Policy (18101)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (514)
Accelerated approval (30)
ADA (21)
Adcomms (1)
Allergies (97)
Alliances (33593)
ALS (108)
Alzheimer's disease (988)
Antibody-drug conjugate (ADC) (283)
Approvals (10491)
Artificial intelligence (336)
ASCO (160)
Autoimmune disease (220)
Automation (29)
Bankruptcy (264)
Best Places to Work (6983)
BIO (36)
Biologics (9)
BIOSECURE Act (2)
Biosimilars (133)
BioSpace Insights (18)
Biotechnology (88)
Bladder cancer (140)
Brain cancer (30)
Breast cancer (518)
Cancer (3772)
Cardiovascular disease (231)
Career advice (253)
Career pathing (1)
CAR-T (177)
CDMO (12)
Celiac Disease (1)
Cell therapy (488)
Cervical cancer (35)
Clinical research (48446)
Collaboration (1307)
Commercialization (3)
Compensation (1519)
Complete response letters (34)
COVID-19 (770)
CRISPR (64)
C-suite (802)
Cystic fibrosis (92)
Data (5842)
Denatured (4)
Depression (104)
Dermatology (69)
Diabetes (355)
Diagnostics (4212)
Digital health (41)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (161)
Drug pricing (29)
Drug shortages (2)
Duchenne muscular dystrophy (166)
Earnings (73913)
Editorial (2)
Employer branding (3)
Employer resources (15)
Events (88299)
Executive appointments (722)
FDA (12557)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (25)
Funding (962)
Gene editing (126)
Generative AI (11)
Gene therapy (336)
GLP-1 (359)
Government (1004)
Grass and pollen (2)
Guidances (281)
Healthcare (9440)
Hematology (94)
HIV (53)
Huntington's disease (22)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (66)
Immunology and inflammation (111)
Immuno-oncology (62)
Indications (161)
Infectious disease (963)
Inflammatory bowel disease (130)
Inflation Reduction Act (5)
Influenza (86)
Intellectual property (261)
Interviews (45)
IPO (12444)
IRA (12)
Job creations (1999)
Job search strategy (242)
JPM (1)
Kidney cancer (16)
Labor market (2)
Layoffs (66)
Legal (5257)
Licensing (17)
Liver cancer (45)
Longevity (19)
Lung cancer (548)
Lymphoma (257)
Machine learning (29)
Management (3)
Manufacturing (558)
Marketing (8)
MASH (133)
Medical affairs (2)
Medical device (8676)
Medtech (8830)
Mergers & acquisitions (14481)
Metabolic disorders (767)
mRNA (64)
Multiple sclerosis (105)
NASH (10)
Neurodegenerative disease (225)
Neuropsychiatric disorders (43)
Neuroscience (1869)
NextGen: Class of 2026 (3187)
Non-profit (864)
Obesity (261)
Opinion (18)
Ovarian cancer (161)
Pain (176)
Pancreatic cancer (204)
Parkinson's disease (206)
Partnered (12)
Patents (493)
Patient recruitment (523)
Peanut (31)
People (41627)
Peptides (1)
Pharmaceutical (30)
Pharmacy benefit managers (12)
Phase 1 (15615)
Phase 2 (21582)
Phase 3 (14637)
Pipeline (7655)
Policy (34)
Postmarket research (1637)
Preclinical (6585)
Press Release (34)
Prostate cancer (193)
Psychedelics (7)
Radiopharmaceuticals (193)
Rare diseases (599)
Real estate (3053)
Recruiting (7)
Regulatory (15039)
Reports (24)
Research institute (603)
Resumes & cover letters (47)
Rett syndrome (42)
RNA editing (6)
RSV (48)
Schizophrenia (110)
Series A (166)
Series B (126)
Service/supplier (5)
Sickle cell disease (63)
Special edition (1)
Spinal muscular atrophy (89)
Sponsored (5)
Startups (2055)
Stomach cancer (3)
Supply chain (52)
The Weekly (6)
Vaccines (338)
Venture capital (22)
Weight loss (103)
Women's health (83)
Date
Today (84)
Last 7 days (376)
Last 30 days (1500)
Last 365 days (19202)
2026 (13401)
2025 (19399)
2024 (23154)
2023 (26665)
2022 (34788)
2021 (37415)
2020 (33671)
2019 (23473)
2018 (17615)
2017 (18985)
2016 (18062)
2015 (24436)
2014 (21812)
2013 (18299)
2012 (20364)
2011 (20531)
2010 (20425)
Location
Africa (241)
Alabama (75)
Alaska (2)
Arizona (308)
Arkansas (11)
Asia (18107)
Australia (2144)
California (12280)
Canada (3217)
China (544)
Colorado (490)
Connecticut (442)
Delaware (210)
Europe (26410)
Florida (1839)
Georgia (390)
Hawaii (3)
Idaho (46)
Illinois (721)
India (53)
Indiana (320)
Iowa (16)
Japan (422)
Kansas (101)
Kentucky (31)
Louisiana (27)
Maine (26)
Maryland (1221)
Massachusetts (8070)
Michigan (312)
Minnesota (568)
Mississippi (4)
Missouri (83)
Montana (20)
Nebraska (11)
Nevada (119)
New Hampshire (60)
New Jersey (2675)
New Mexico (12)
New York (2882)
North Carolina (1311)
North Dakota (4)
Northern California (6172)
Ohio (288)
Oklahoma (15)
Oregon (16)
Pennsylvania (2293)
Puerto Rico (20)
Rhode Island (30)
South America (415)
South Carolina (77)
South Dakota (1)
Southern California (5103)
Tennessee (122)
Texas (1990)
United States (39822)
Utah (366)
Vermont (1)
Virginia (156)
Washington D.C. (40)
Washington State (953)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
488,659 Results for "boehringer ingelheim vetmedica inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pipeline
Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’
Not much is known about Boehringer Ingelheim’s drug candidate, dubbed BI 3031185, though the asset has completed at least two other Phase 1 studies this year.
August 24, 2026
·
1 min read
·
Tristan Manalac
Press Releases
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies
· New research team expands capabilities at Boehringer’s U.S. R&D site in Ridgefield, Connecticut.
July 9, 2026
·
1 min read
Press Releases
Boehringer Ingelheim Spotlights Next Generation of Veterinary Researchers
August 10, 2026
·
5 min read
Press Releases
Boehringer Ingelheim expands equine health pipeline with acquisition of Evax AG
August 11, 2026
·
3 min read
Press Releases
Boehringer Ingelheim Celebrates Grand Opening of New U.S. Animal Health Headquarters in Johns Creek, Georgia
August 31, 2026
·
3 min read
Press Releases
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim
September 2, 2026
·
1 min read
Policy
Germany rethinking drug price reforms after Lilly, Boehringer withdraw investments:
Reuters
Weeks after Boehringer Ingelheim and Eli Lilly retracted billions of dollar in German commitments, the nation’s government is reportedly changing a contentious element of its planned healthcare reforms.
June 15, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
Zomedica Announces Strategic Collaboration with Boehringer Ingelheim Animal Health Canada Inc. to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform
August 13, 2026
·
9 min read
Obesity
ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction
While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.
June 8, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Lilly and Boehringer roll back billions in German investments over health budget cuts
With Germany moving to curb healthcare spending, Eli Lilly and Boehringer Ingelheim have rethought plans to invest in facilities, including a manufacturing plant for GLP-1 drugs.
June 4, 2026
·
2 min read
·
Nick Paul Taylor
1 of 48,866
Next
